TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab (Q34418098)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22989378%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

title

TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22989378%20AND%20SRC:MED&resulttype=core&format=json

relapsing-remitting multiple sclerosis

13 February 2020

main subject

multiple sclerosis

0 references

0 references

author

Exuperio Díez Tejedor

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22989378%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

author name string

Celia Oreja-Guevara

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22989378%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Jaime Ramos-Cejudo

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22989378%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Luiz Stark Aroeira

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22989378%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Beatriz Chamorro

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22989378%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

publication date

18 September 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22989378%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22989378%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22989378%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

page(s)

95

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22989378%20AND%20SRC:MED&resulttype=core&format=json

Treatment with natalizumab in relapsing-remitting multiple sclerosis patients induces changes in inflammatory mechanism

13 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517482

Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517482

Therapeutic targeting of chemokine signaling in Multiple Sclerosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517482

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517482

The expression and function of chemokines involved in CNS inflammation

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517482

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517482

Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517482

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517482

Cytokines in multiple sclerosis: from bench to bedside

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517482

Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517482

Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517482

Bio-markers of disease activity and response to therapy in multiple sclerosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517482

Experimental autoimmune encephalomyelitis: cytokines, effector T cells, and antigen-presenting cells in a prototypical Th1-mediated autoimmune disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517482

The lineage decisions of helper T cells

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517482

Antigen specific immunotherapy of multiple sclerosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517482

Treatment of multiple sclerosis with Copaxone (COP): Elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517482

Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517482

Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517482

Interferon-gamma-induced oligodendrocyte cell death: implications for the pathogenesis of multiple sclerosis.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517482

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517482

Association between Tumor Necrosis Factor-α and Disease Progression in Patients with Multiple Sclerosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517482

Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b

6 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-12-95

Effect of interferon-beta and atorvastatin on Th1/Th2 cytokines in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-12-95

Glatiramer acetate: mechanisms of action in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-12-95

IFN-beta1a and IFN-beta1b have different patterns of influence on cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-12-95

Glatiramer Acetate (Copolymer-1, Copaxone) Promotes Th2 Cell Development and Increased IL-10 Production Through Modulation of Dendritic Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-12-95

A controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-12-95

Clinical and immune responses correlate in glatiramer acetate therapy of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-12-95

The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-12-95

Natalizumab: bound to rebound?

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-12-95

Natalizumab effects on immune cell responses in multiple sclerosis

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3517482

Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis

27 October 2018

1 reference

12 December 2020

Immunology of multiple sclerosis

1 reference

12 December 2020

Clinical response to glatiramer acetate correlates with modulation of IFN-gamma and IL-4 expression in multiple sclerosis

1 reference

12 December 2020

Induction of systemic TNFalpha in natalizumab-treated multiple sclerosis

1 reference

12 December 2020

Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients

1 reference

12 December 2020

Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression

1 reference

12 December 2020

Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid

1 reference

12 December 2020

Patterns of TH1/TH2 cytokines predict clinical response in multiple sclerosis patients treated with glatiramer acetate

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2377-12-95

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22989378%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

13 February 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22989378%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

PubMed publication ID

22989378

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22989378%20AND%20SRC:MED&resulttype=core&format=json